8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
May 6, 2026·SEC
Actuate Therapeutics Inc(ACTU)Earnings, Financials & Key Ratios
ACTU•NASDAQ
Price updated Jun 13, 2026
AboutActuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Show more
- Revenue$0
- EBITDA-$22M+2.3%
- Net Income-$22M+18.5%
- EPS (Diluted)-1.06+67.5%
- ROE-553.75%+97.9%
- Debt/Equity0.05
- Interest Coverage-1110.84+23.9%
ACTU Key Insights
Actuate Therapeutics Inc (ACTU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACTU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACTU Price & Volume
Actuate Therapeutics Inc (ACTU) stock price & volume — 10-year historical chart
Loading chart...
ACTU Growth Metrics
Actuate Therapeutics Inc (ACTU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.3%
Return on Capital
10 Years-1479.87%
5 Years-1479.87%
3 Years-1931.42%
Last Year-508.66%
ACTU Peer Comparison
Actuate Therapeutics Inc (ACTU) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 6.9B | 33.62 | -12.14 | -68.16% | 0.00 | |||
 TPVG | 226.14M | 5.57 | 4.57 | 36.55% | -19.55% | -3.39% | 1.33 | |
 AGIO | 1.75B | 29.46 | -4.14 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PRAX | 7.7B | 266.54 | -19.77 | -100% | -43.02% | 0.00 | ||
 IDYA | 2.55B | 28.98 | -22.64 | 30.24% | -62.17% | -13.96% | 0.03 | |
 MGNX | 251.71M | 3.96 | -3.36 | 0.78% | -44.79% | -147.8% | 1.92 | |
 NKTR | 1.16B | 59.38 | -6.10 | -43.89% | -284.18% | -87% | 1.66 | |
 CRVS | 1B | 11.93 | -22.51 | -38.92% | 0.02 |
Compare ACTU vs Peers
Actuate Therapeutics Inc (ACTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACTU Income Statement
Actuate Therapeutics Inc (ACTU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - |
Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M | 21.83M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M | 12.2M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 16.39M | 21.71M | 18.68M | 10.29M | 9.64M |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
Operating Income | -20.21M▲ 0% | -24.97M▼ 23.6% | -25.16M▼ 0.7% | -22.5M▲ 10.6% | -21.83M▲ 0% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | -23.59% | -0.75% | 10.59% | - |
EBITDA | -20.14M | -24.7M | -23.02M | -22.5M | -21.74M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | -22.63% | 6.82% | 2.27% | 14.03% |
D&A (Non-Cash Add-back) | 63.61K | 272.85K | 2.14M | 0 | 0 |
EBIT | -20.14M | -24.7M | -27.3M | -22.49M | -21.74M |
Net Interest Income | 10.83K | 309.03K | 241.01K | 267.46K | 299.11K |
Interest Income | 27.03K | 352.67K | 222.29K | 287.71K | 319.36K |
Interest Expense | 16.2K | 43.64K | -18.72K | 20.25K | 20.25K |
Other Income/Expense | 47.41K | 229.21K | -2.12M | 267.46K | 299.11K |
Pretax Income | -20.16M▲ 0% | -24.74M▼ 22.7% | -27.28M▼ 10.3% | -22.23M▲ 18.5% | -21.54M▲ 0% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 0 | 0 | 800 | 0 | 800 |
Effective Tax Rate % | 0% | 0% | -0% | 0% | -0% |
Net Income | -20.16M▲ 0% | -24.74M▼ 22.7% | -27.29M▼ 10.3% | -22.23M▲ 18.5% | -21.54M▲ 0% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | -22.74% | -10.27% | 18.54% | 14.9% |
Net Income (Continuing) | -20.16M | -24.74M | -27.29M | -22.23M | -21.54M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.34▲ 0% | -1.65▼ 23.1% | -3.26▼ 97.6% | -1.06▲ 67.5% | -0.92▲ 0% |
EPS Growth % | - | -23.13% | -97.58% | 67.48% | 45.3% |
EPS (Basic) | -1.34 | -1.65 | -3.26 | -1.06 | - |
Diluted Shares Outstanding | 15.03M | 15.03M | 19.51M | 21.02M | 23.54M |
Basic Shares Outstanding | 15.03M | 15.03M | 19.51M | 21.02M | 23.54M |
Dividend Payout Ratio | - | - | - | - | - |
ACTU Balance Sheet
Actuate Therapeutics Inc (ACTU) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 20.48M | 3M | 9.21M | 13.64M | 8.52M |
Cash & Short-Term Investments | 20.45M | 2.96M | 8.64M | 13.16M | 8.13M |
Cash Only | 20.45M | 2.96M | 8.64M | 13.16M | 8.13M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 33.75K | 36.91K | 0 | 484K | 385.44K |
Total Non-Current Assets | 0 | 0 | 110.55K | 392.49K | 391.84K |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 110.55K | 392.49K | 391.84K |
Total Assets | 20.48M▲ 0% | 3M▼ 85.4% | 9.32M▲ 211.1% | 14.04M▲ 50.6% | 8.91M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x |
Asset Growth % | - | -85.38% | 211.07% | 50.63% | 476.23% |
Total Current Liabilities | 4.34M | 6.92M | 8.8M | 5.71M | 4.72M |
Accounts Payable | 2.13M | 3.42M | 1.92M | 1.52M | 1.2M |
Days Payables Outstanding | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.08M | 277.5K | 0 | 4.18M | 3.52M |
Current Ratio | 4.71x | 0.43x | 1.05x | 2.39x | 1.80x |
Quick Ratio | 4.71x | 0.43x | 1.05x | 2.39x | 1.80x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 1.31M | 95.7M | 411.76K | 404.99K | 404.99K |
Long-Term Debt | 404.99K | 0 | 0 | 404.99K | 404.99K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 900.76K | 95.7M | 411.76K | 0 | 0 |
Total Liabilities | 5.65M | 102.62M | 9.21M | 6.11M | 5.13M |
Total Debt | 404.99K | 0 | 0 | 404.99K | 404.99K |
Net Debt | -20.04M | -2.96M | -8.64M | -12.75M | -7.73M |
Debt / Equity | 0.03x | - | - | 0.05x | 0.11x |
Debt / EBITDA | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | 0.36x |
Interest Coverage | -1243.41x | -566.00x | -1458.78x | -1110.84x | -1073.65x |
Total Equity | 14.83M▲ 0% | -99.63M▼ 771.7% | 104.19K▲ 100.1% | 7.92M▲ 7505.6% | 3.78M▲ 0% |
Equity Growth % | - | -771.69% | 100.1% | 7505.63% | 7881.78% |
Book Value per Share | 0.99 | -6.63 | 0.01 | 0.38 | 0.16 |
Total Shareholders' Equity | 14.83M | -99.63M | 104.19K | 7.92M | 3.78M |
Common Stock | 3 | 2 | 20 | 23 | 24 |
Retained Earnings | -80.35M | -105.09M | -132.38M | -154.61M | -160.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
ACTU Cash Flow Statement
Actuate Therapeutics Inc (ACTU) cash flow — operating, investing & free cash flow history
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -17.79M | -21.63M | -21.84M | -19.21M | -19.78M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -21.53% | -1.01% | 12.07% | -22.56% |
Net Income | -20.16M | -24.74M | -27.29M | -22.23M | -21.54M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 654.07K | 423.54K | 2M | 6.05M | 4.7M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -20.38K | 123.46K | 2.35M | 20.25K | 1.56M |
Working Capital Changes | 1.73M | 2.57M | 1.1M | -3.05M | -4.5M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 586.26K | 1.29M | -1.5M | -512.54K | -1.46M |
Cash from Investing | 0 | 0 | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 19.26M | 4.13M | 27.53M | 23.72M | 24.02M |
Debt Issued (Net) | 0 | 0 | 5.5M | 0 | 0 |
Equity Issued (Net) | 19.26M | 4.13M | 23.96M | 24.03M | 24.68M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -1.93M | -302.82K | -655.32K |
Net Change in Cash | 1.46M▲ 0% | -17.49M▼ 1296.8% | 5.68M▲ 132.5% | 4.52M▼ 20.5% | 4.24M▲ 0% |
Free Cash Flow | -17.79M▲ 0% | -21.63M▼ 21.5% | -21.84M▼ 1.0% | -19.21M▲ 12.1% | -19.78M▲ 0% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | -21.53% | -1.01% | 12.07% | 6.76% |
FCF per Share | -1.18 | -1.44 | -1.12 | -0.91 | -0.84 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.87x | 0.80x | 0.86x | 0.92x |
Interest Paid | 0 | 0 | 71.03K | 0 | 70.96K |
Taxes Paid | 0 | 0 | 800 | 0 | 0 |
ACTU Key Ratios
Actuate Therapeutics Inc (ACTU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | - | -26189.05% | -553.75% | -430.93% |
| Return on Invested Capital (ROIC) | - | - | - | 273.96% |
| Debt / Equity | - | - | 0.05x | 0.11x |
| Interest Coverage | -566.00x | -1458.78x | -1110.84x | -1073.65x |
| FCF Conversion | 0.87x | 0.80x | 0.86x | 0.92x |
Related:ACTU Dividend History·ACTU Revenue History·ACTU Price History·ACTU P/E History·ACTU Financial Ratios·ACTU Institutional Holders
ACTU SEC Filings & Documents
Actuate Therapeutics Inc (ACTU) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACTU Frequently Asked Questions
Actuate Therapeutics Inc (ACTU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Actuate Therapeutics Inc (ACTU) grew revenue by 0.0% over the past year. Growth has been modest.
Actuate Therapeutics Inc (ACTU) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
Actuate Therapeutics Inc (ACTU) has a return on equity (ROE) of -553.7%. Negative ROE indicates the company is unprofitable.
Actuate Therapeutics Inc (ACTU) had negative free cash flow of $19.8M in fiscal year 2025, likely due to heavy capital investments.